S7201
SR-46349 hemifumarate salt
≥98% (HPLC)
别名:
4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate salt, Eplivanserin hemifumarate salt, SR-46349B
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H21FN2O2 · 0.5 C4H4O4
化学文摘社编号:
分子量:
386.42
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+
SMILES string
OC(=O)\C=C\C(O)=O.CN(C)CCO\N=C(\C=C\c1ccc(O)cc1)c2ccccc2F.CN(C)CCO\N=C(\C=C\c3ccc(O)cc3)c4ccccc4F
InChI key
RNLKLYQQDLHHBH-ABDBJYMXSA-N
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
color
white to off-white
solubility
DMSO: ≥10 mg/mL
originator
Sanofi Aventis
storage temp.
2-8°C
Quality Level
Gene Information
human ... HTR2A(3356)
Application
SR-46349 hemifumarate salt may be used in cell signaling studies.
Biochem/physiol Actions
ASTAR (Antagonist of Serotonin 5HT2A Receptors).
SR-46349 is an antagonist of 5-HT (2A/2C) receptor and increases the release of dopamine by medial prefrontal cortex in rats.1 It increases the signal transduction induced by 5-HT2 receptor by binding with high affinity.2 SR-46349 inhibits the aggregation of rabbit and human platelets in response to serotonin.3
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Christophe Lanteri et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 29(4), 987-997 (2009-01-30)
Although nicotine is generally considered to be the main compound responsible for addictive properties of tobacco, experimental data indicate that nicotine does not exhibit all the characteristics of other substances of abuse. We recently showed that a pretreatment with mixed
Stefania Bonaccorso et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 27(3), 430-441 (2002-09-13)
The combination of M100907, a putative antipsychotic drug (APD) and serotonin (5-HT)(2A) antagonist, and the typical APD haloperidol, can enhance dopamine (DA) release in rat medial prefrontal cortex (mPFC), an effect which has been postulated to be of value to
Kevin T Ball et al.
Psychopharmacology, 181(4), 676-687 (2005-07-08)
Like amphetamine, a locomotor-activating dose of 3,4-methylenedioxymethamphetamine (MDMA) predominantly excites striatal single-unit activity in freely moving rats. Although both D1- and D2-like dopamine (DA) receptors play important roles in this effect, MDMA, unlike amphetamine, strongly increases both DA and serotonin
J M Herbert et al.
Thrombosis and haemostasis, 69(3), 262-267 (1993-03-01)
SR 46349 (trans-4-[(3Z)3-(2-dimethylaminoethyl)oxyimino-3(2-fluorophe nyl) propen-1-yl] phenol, hemifumarate) is the first member of a newly-developed 5-HT2 antagonist series. SR 46349 potently inhibited serotonin-induced aggregation of rabbit and human platelets (IC50 = 1 and 3.9 nM respectively) but had no effect on
Agnès Auclair et al.
The European journal of neuroscience, 20(11), 3073-3084 (2004-12-08)
Addictive properties of drugs of misuse are generally considered to be mediated by an increased release of dopamine (DA) in the ventral striatum. However, recent experiments indicated an implication of alpha1b-adrenergic receptors in behavioural responses to psychostimulants and opiates. We
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持